# A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL

> **NCT00858117** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 30 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** Alemtuzumab
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT00858117
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09-26
- **Primary completion:** 2010-03-17
- **Final completion:** 2013-01-24
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00858117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00858117, "A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00858117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*